(Massachusetts General Hospital) Investigators at the Massachusetts General Hospital Cancer Center have defined the role of a recently identified gene abnormality - rearrangements in the ROS1 gene - in a deadly form of lung cancer.
ROS1-rearranged tumors represent one to two percent of non-small-cell lung cancers, the leading cause of cancer death in the US.
The researchers also show that ROS1-driven tumors can be treated with crizotinib and describe the remarkable response of one patient to crizotinib treatment.